KRAS and colorectal carcinoma: In approximately 35.0%-42.0% of early colorectal cancer (CRC) pa­tients, KRAS mutations inhibit KRAS GTPase, resulting in constitutive activation of KRAS, and in turn, activation of the RAS/RAF signaling pathway.